Applied Therapeutics
Applied Therapeutics
APLT
NASDAQ
0.52
USD
4.00%
About
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG.
The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed.
The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 957.0K |
| Three Month Average Volume | 25.9M |
| High Low | |
| Fifty-Two Week High | 9.39 USD |
| Fifty-Two Week Low | 1.22 USD |
| Fifty-Two Week High Date | 28 Feb 2024 |
| Fifty-Two Week Low Date | 05 Sep 2023 |
| Price and Volume | |
| Current Price | 6.34 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.89% |
| Thirteen Week Relative Price Change | 38.40% |
| Twenty-Six Week Relative Price Change | -18.44% |
| Fifty-Two Week Relative Price Change | 280.42% |
| Year-to-Date Relative Price Change | 59.82% |
| Price Change | |
| One Day Price Change | 4.28% |
| Thirteen Week Price Change | 48.13% |
| Twenty-Six Week Price Change | -10.33% |
| Five Day Price Change | 9.88% |
| Fifty-Two Week Price Change | 376.69% |
| Year-to-Date Price Change | 89.25% |
| Month-to-Date Price Change | 6.73% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.20203 USD |
| Book Value Per Share (Most Recent Quarter) | 0.63034 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.20203 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.63034 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.68961 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.11862 USD |
| Revenue Per Share (Trailing Twelve Months) | -0.00294 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.42161 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.51832 USD |
| Normalized (Last Fiscal Year) | -1.42161 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.42161 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.51721 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.42161 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.51832 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.59093 USD |
| Cash Per Share (Most Recent Quarter) | 1.06621 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.42161 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.42359 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.64722 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -3,387 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -1,198.47% |
| Pretax Margin (5 Year) | -4,476.42% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -645.80% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -3,934.26% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,198.47% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -4,476.42% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -103.12% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 105.08% |
| EPS Change (Trailing Twelve Months) | -22.36% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | 10 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -122,450,000 |
| Net Debt (Last Fiscal Year) | -50,152,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 73 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | 10 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -55,173,000 |
| Free Cash Flow (Trailing Twelve Months) | -73,237,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -257.01% |
| Return on Assets (Trailing Twelve Months) | -187.94% |
| Return on Assets (5 Year) | -140.37% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -473.39% |
| Return on Equity (5 Year) | -274.81% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -467.74% |
| Return on Investment (5 Year) | -240.93% |